Document is current
Any future updates will be listed below
-
Authors
Osugo, Martin https://orcid.org/0000-0002-5462-8464
Wall, Matthew B.
Selvaggi, Pierluigi
Zahid, Uzma
Finelli, Valeria https://orcid.org/0009-0006-1026-4626
Chapman, George E.
Whitehurst, Thomas
Onwordi, Ellis Chika
Statton, Ben https://orcid.org/0000-0001-5118-7977
McCutcheon, Robert A.
Murray, Robin M. https://orcid.org/0000-0003-0829-0519
Marques, Tiago Reis https://orcid.org/0000-0003-0602-7661
Mehta, Mitul A. https://orcid.org/0000-0003-1152-5323
Howes, Oliver D. https://orcid.org/0000-0002-2928-1972
-
Funding
Funding for this research was provided by:
RCUK | Medical Research Council (MC_ U120097115)
- License Information
-
More Information
Article History
Received: 23 August 2024
Accepted: 23 January 2025
First Online: 21 February 2025
Competing interests
: O.D.H. has received investigator-initiated research funding from and/or participated in advisory/speaker meetings organised by Angellini, Autifony, Biogen, Boehringer-Ingelheim, Eli Lilly, Elysium, Heptares, Global Medical Education, Invicro, Jansenn, Karuna, Lundbeck, Merck, Neurocrine, Ontrack/ Pangea, Otsuka, Sunovion, Recordati, Roche, Rovi and Viatris/Mylan. He was previously a part-time employee of Lundbeck A/v. Neither O.D.H. nor his family have holdings/a financial stake in any pharmaceutical company. M.B.W. is an employee of Perceptive Inc., London. T.R.M. is an employee and founder of Pasithea Therapeutics. R.A.M. has received speaker/consultancy fees from Boehringer Ingelheim, Janssen, Karuna, Lundbeck, Otsuka, and Viatris, and co-directs a company that designs digital resources to support the treatment of mental ill health. Other authors have reported no biomedical financial interests or potential conflicts of interest.
